Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Association of proliferative diabetic retinopathy with insulin use and microalbuminuria.

Chu SH, Li AH.

Arch Ophthalmol. 2010 Jan;128(1):146; author reply 146-7. doi: 10.1001/archophthalmol.2009.363. No abstract available. Erratum in: Arch Ophthalmol. 2011 Apr;129(4):413. Chun, Shu-Hsun [corrected to Chu, Shu-Hsun].

PMID:
20065240
2.

Rosiglitazone and delayed onset of proliferative diabetic retinopathy.

Shen LQ, Child A, Weber GM, Folkman J, Aiello LP.

Arch Ophthalmol. 2008 Jun;126(6):793-9. doi: 10.1001/archopht.126.6.793.

PMID:
18541841
3.

Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus.

Tatti P, Arrigoni F, Longobardi A, Costanza F, Di Blasi P, Merante D.

Clin Drug Investig. 2008;28(5):327-32.

PMID:
18407718
4.

Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study.

Oshitari T, Asaumi N, Watanabe M, Kumagai K, Mitamura Y.

Vasc Health Risk Manag. 2008;4(5):1137-40.

5.

Macular edema and thiazolidinediones.

Colucciello M, Ryan E.

Arch Ophthalmol. 2010 Dec;128(12):1630-1; author reply 1631-2. doi: 10.1001/archophthalmol.2010.287. No abstract available.

PMID:
21149797
6.

A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.

Lehmann DF, Lohray BB.

J Clin Pharmacol. 2008 Aug;48(8):999-1002. doi: 10.1177/0091270008319791. No abstract available.

PMID:
18650500
7.

Pioglitazone associated diabetic macular oedema.

Gokce G, Durukan AH, Erdurman FC, Ceylan OM, Sobaci G.

West Indian Med J. 2012 Sep;61(6):648-9. No abstract available.

PMID:
23441365
8.

Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy.

Kitzmiller JL, Main E, Ward B, Theiss T, Peterson DL.

Diabetes Care. 1999 May;22(5):874-6. No abstract available.

9.

[The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].

Szymborska-Kajanek A, Strojek K.

Kardiol Pol. 2006 Mar;64(3):322-5; discussion 325-6. Review. Polish. No abstract available.

10.

Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.

Odom J, Williamson B, Carter L.

Am J Health Syst Pharm. 2008 Oct 1;65(19):1846-50. doi: 10.2146/ajhp070659. No abstract available.

PMID:
18796427
11.

Glitazone use associated with diabetic macular edema.

Fong DS, Contreras R.

Am J Ophthalmol. 2009 Apr;147(4):583-586.e1. doi: 10.1016/j.ajo.2008.10.016. Epub 2009 Feb 1.

PMID:
19181303
12.

[Diabetic edematous maculopathy associated with rosiglitazone treatment: report of a case].

Nyssen V, Hautenauven F, Lekeu Hinostroza JP, Guagnini AP.

Bull Soc Belge Ophtalmol. 2009;(313):39-44. French.

PMID:
20108571
13.

Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes".

Singh S, Segal JB.

Arch Intern Med. 2012 Jul 9;172(13):1011-3. doi: 10.1001/archinternmed.2012.2461. No abstract available.

PMID:
22688825
14.
15.

Future directions for insulin sensitizers in disease prevention.

Colca JR.

Curr Opin Investig Drugs. 2007 Sep;8(9):707-10. Review. No abstract available.

PMID:
17729181
16.
17.

The PROactive study: some answers, many questions.

Yki-Järvinen H.

Lancet. 2005 Oct 8;366(9493):1241-2. No abstract available.

PMID:
16214581
18.

Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?

Consoli A, Formoso G.

Diabetes Obes Metab. 2013 Nov;15(11):967-77. doi: 10.1111/dom.12101. Epub 2013 Apr 18. Review.

PMID:
23522285
19.

PPAR-gamma agonists and their role in type 2 diabetes mellitus management.

Bermúdez V, Finol F, Parra N, Parra M, Pérez A, Peñaranda L, Vílchez D, Rojas J, Arráiz N, Velasco M.

Am J Ther. 2010 May-Jun;17(3):274-83. doi: 10.1097/MJT.0b013e3181c08081.

PMID:
20216208
20.

Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.

Savage S, Estacio RO, Jeffers B, Schrier RW.

Proc Assoc Am Physicians. 1997 Mar;109(2):181-9.

PMID:
9069587

Supplemental Content

Support Center